BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 16868548)

  • 1. Targeting of somatic hypermutation.
    Odegard VH; Schatz DG
    Nat Rev Immunol; 2006 Aug; 6(8):573-83. PubMed ID: 16868548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA targets of AID evolutionary link between antibody somatic hypermutation and class switch recombination.
    Hackney JA; Misaghi S; Senger K; Garris C; Sun Y; Lorenzo MN; Zarrin AA
    Adv Immunol; 2009; 101():163-89. PubMed ID: 19231595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Episomal vectors to monitor and induce somatic hypermutation in human Burkitt-Lymphoma cell lines.
    Rückerl F; Busse B; Bachl J
    Mol Immunol; 2006 Apr; 43(10):1645-52. PubMed ID: 16310251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation-induced cytidine deaminase turns on somatic hypermutation in hybridomas.
    Martin A; Bardwell PD; Woo CJ; Fan M; Shulman MJ; Scharff MD
    Nature; 2002 Feb; 415(6873):802-6. PubMed ID: 11823785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of AID in tumorigenesis.
    Okazaki IM; Kotani A; Honjo T
    Adv Immunol; 2007; 94():245-73. PubMed ID: 17560277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A/T-targeted somatic hypermutation: critique of the mainstream model.
    Franklin A; Blanden RV
    Trends Biochem Sci; 2006 May; 31(5):252-8. PubMed ID: 16616496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biased dA/dT somatic hypermutation as regulated by the heavy chain intronic iEmu enhancer and 3'Ealpha enhancers in human lymphoblastoid B cells.
    Komori A; Xu Z; Wu X; Zan H; Casali P
    Mol Immunol; 2006 Apr; 43(11):1817-26. PubMed ID: 16412510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control of gene conversion and somatic hypermutation by immunoglobulin promoter and enhancer sequences.
    Yang SY; Fugmann SD; Schatz DG
    J Exp Med; 2006 Dec; 203(13):2919-28. PubMed ID: 17178919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AID mutates a non-immunoglobulin transgene independent of chromosomal position.
    Parsa JY; Basit W; Wang CL; Gommerman JL; Carlyle JR; Martin A
    Mol Immunol; 2007 Jan; 44(4):567-75. PubMed ID: 16542725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Presence of somatic hypermutation and activation-induced cytidine deaminase in acute lymphoblastic leukemia L2 with t(14;18)(q32;q21).
    Hardianti MS; Tatsumi E; Syampurnawati M; Furuta K; Suzuki A; Saigo K; Kawano S; Takenokuchi M; Kumagai S; Matsuo Y; Koizumi T; Takeuchi M
    Eur J Haematol; 2005 Jan; 74(1):11-9. PubMed ID: 15613101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation-induced deaminase: light and dark sides.
    de Yébenes VG; Ramiro AR
    Trends Mol Med; 2006 Sep; 12(9):432-9. PubMed ID: 16861038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reflections on the state of play in somatic hypermutation.
    Steele EJ
    Mol Immunol; 2008 May; 45(10):2723-6. PubMed ID: 18359085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topologically Associated Domains Delineate Susceptibility to Somatic Hypermutation.
    Senigl F; Maman Y; Dinesh RK; Alinikula J; Seth RB; Pecnova L; Omer AD; Rao SSP; Weisz D; Buerstedde JM; Aiden EL; Casellas R; Hejnar J; Schatz DG
    Cell Rep; 2019 Dec; 29(12):3902-3915.e8. PubMed ID: 31851922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A target selection of somatic hypermutations is regulated similarly between T and B cells upon activation-induced cytidine deaminase expression.
    Kotani A; Okazaki IM; Muramatsu M; Kinoshita K; Begum NA; Nakajima T; Saito H; Honjo T
    Proc Natl Acad Sci U S A; 2005 Mar; 102(12):4506-11. PubMed ID: 15767564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strand-biased spreading of mutations during somatic hypermutation.
    Unniraman S; Schatz DG
    Science; 2007 Aug; 317(5842):1227-30. PubMed ID: 17761884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A critical context-dependent role for E boxes in the targeting of somatic hypermutation.
    McDonald JJ; Alinikula J; Buerstedde JM; Schatz DG
    J Immunol; 2013 Aug; 191(4):1556-66. PubMed ID: 23836058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infection of human B cells with Epstein-Barr virus results in the expression of somatic hypermutation-inducing molecules and in the accrual of oncogene mutations.
    Epeldegui M; Hung YP; McQuay A; Ambinder RF; Martínez-Maza O
    Mol Immunol; 2007 Feb; 44(5):934-42. PubMed ID: 16730063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AID and Igh switch region-Myc chromosomal translocations.
    Unniraman S; Schatz DG
    DNA Repair (Amst); 2006 Sep; 5(9-10):1259-64. PubMed ID: 16784901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two levels of protection for the B cell genome during somatic hypermutation.
    Liu M; Duke JL; Richter DJ; Vinuesa CG; Goodnow CC; Kleinstein SH; Schatz DG
    Nature; 2008 Feb; 451(7180):841-5. PubMed ID: 18273020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of core DNA elements that target somatic hypermutation.
    Kohler KM; McDonald JJ; Duke JL; Arakawa H; Tan S; Kleinstein SH; Buerstedde JM; Schatz DG
    J Immunol; 2012 Dec; 189(11):5314-26. PubMed ID: 23087403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.